-
Signature
-
/s/Steven Adams, Attorney-in-Fact
-
Stock symbol
-
ATNXQ
-
Transactions as of
-
Apr 21, 2023
-
Transactions value $
-
$500
-
Form type
-
4
-
Date filed
-
4/24/2023, 04:29 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
ATNXQ |
Common Stock |
Award |
$500 |
+383 |
+11.3% |
$1.31 |
3.77K |
Apr 21, 2023 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
holding |
ATNXQ |
Stock Option (Right to Buy) |
|
|
|
|
|
3.5K |
Apr 21, 2023 |
Common Stock |
3.5K |
$345.80 |
Direct |
|
holding |
ATNXQ |
Stock Option (Right to Buy) |
|
|
|
|
|
1.5K |
Apr 21, 2023 |
Common Stock |
1.5K |
$205.20 |
Direct |
F2 |
holding |
ATNXQ |
Stock Option (Right to Buy) |
|
|
|
|
|
450 |
Apr 21, 2023 |
Common Stock |
450 |
$71.20 |
Direct |
F3 |
holding |
ATNXQ |
Restricted Stock Units |
|
|
|
|
|
338 |
Apr 21, 2023 |
Common Stock |
338 |
|
Direct |
F4, F5 |
holding |
ATNXQ |
Stock Option (Right to Buy) |
|
|
|
|
|
3.75K |
Apr 21, 2023 |
Common Stock |
3.75K |
$13.31 |
Direct |
F6 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Chief Business and Commercial Officer, Proprietary Drugs